Swine Division

Boehringer Ingelheim Vetmedica, Inc., is a global leader in swine disease research and the development of innovative swine health products and swine diagnostic services to improve pork production.  The swine division works with scientists, researchers, veterinarians, producers, processors and industry leaders to provide solutions to major swine diseases such as porcine reproductive and respiratory syndrome (PRRS), ileitis, Salmonella, erysipelas, Mycoplasma hyopneumoniae and other major swine diseases, as well as emerging diseases such as porcine circovirus associated diseases (PCVAD). 

The swine division of Boehringer Ingelheim Vetmedica, Inc., traces its U.S. roots back to the early 1900s when hog cholera was the devastating disease of the period for hog producers. Over the last 100 years, and after several name changes and acquisitions – including Fermenta Animal Health and NOBL Laboratories, Sioux Center, Iowa, and its Swine Health Management Center, Ames, Iowa – the swine division has been on the cutting edge of swine health innovation.

Key Swine Health Developments:

• Early hog cholera vaccine
• Early E. coli vaccine
• First intranasal atrophic rhinitis vaccine
• Only safe and effective psuedorabies vaccine
• First one-dose oral Salmonella vaccine
• First oral vaccine for Lawsonia ileitis
• First modified-live-virus vaccine for PRRS

Today with nearly 18 swine vaccines and other health products in its swine portfolio, state-of-the-art manufacturing and diagnostic facilities, and industry-leading research programs, Boehringer Ingelheim Vetmedica, Inc., is one of the premiere global swine health companies. More importantly, the swine division continues to seek effective solutions to costly swine health and production problems that challenge the swine industry.